Supplements for OCD: Adjunctive Options with Evide…

Obsessive-compulsive disorder (OCD) is among the most difficult psychiatric conditions to treat. Even with optimal first-line treatment—cognitive behavioral therapy with exposure and response prevention (ERP) plus an SSRI at adequate dose—roughly 40-60% of patients have incomplete responses. This treatment gap has motivated research into adjunctive supplements that might augment standard care. This is not about replacing proven treatments; it is about improving outcomes when they fall short.

Why Standard OCD Treatment Often Fails

OCD requires the highest SSRI doses of any indication. Fluoxetine at 80 mg/day, fluvoxamine at 300 mg/day, sertraline at 200 mg/day—doses that would not be used for depression. Even at these doses, full remission is uncommon. CBT with ERP is the most effective single intervention but is therapist-intensive, requires motivated patients, and is not universally available.

The biological heterogeneity of OCD matters here. Some OCD presentations involve primarily serotonergic dysfunction. Others involve glutamate dysregulation (particularly the cortico-striato-thalamo-cortical circuit). Others involve oxidative stress. Different subtypes may respond to different adjunctive approaches.

Inositol

Inositol at 18 g/day has the best evidence of any supplement for OCD. A 1996 RCT by Fux and colleagues found significant Y-BOCS reductions with 18 g/day inositol vs placebo in a crossover design. As reviewed in our full inositol guide, the mechanism involves the IP3 second messenger pathway and serotonin receptor signaling.

Important caveat: a subsequent RCT found inositol did not enhance the effects of SSRIs when added as augmentation. This suggests inositol may work better as monotherapy or in patients with incomplete SSRI treatment rather than as an add-on to therapeutic doses.

NAC (N-Acetyl Cysteine)

NAC is a precursor to glutathione and a modulator of the cystine-glutamate antiporter in the brain—a system that regulates extracellular glutamate concentrations. In OCD, there is strong evidence of glutamate dysregulation in the cortico-striatal circuits driving compulsive behavior. NAC reduces extracellular glutamate, which may reduce the compulsive urges that characterize OCD.

A 2010 randomized trial by Lafleur and colleagues found NAC augmentation of SSRIs significantly reduced Y-BOCS scores compared to placebo augmentation over 12 weeks. Effect sizes were clinically meaningful. A subsequent smaller trial confirmed benefit.

NAC has also been studied extensively in trichotillomania (hair pulling) and skin picking (excoriation disorder), both OCD-spectrum conditions. A 2009 RCT found NAC at 1,200-2,400 mg/day significantly reduced hair pulling behavior compared to placebo.

The dose for OCD is 1,200-2,400 mg/day (600-1,200 mg twice daily). Common side effects include mild GI symptoms. NAC has a sulfurous smell that some find unpleasant.

Sarcosine

Sarcosine (N-methylglycine) is an endogenous amino acid that inhibits the glycine transporter GlyT1. This increases glycine levels at NMDA receptors, enhancing NMDA receptor function. Given that glutamate-NMDA dysregulation is implicated in OCD, this mechanism is relevant.

A 2016 pilot RCT found sarcosine augmentation of SSRIs significantly superior to placebo augmentation for OCD symptoms at 12 weeks. The effect was large. This is early-stage evidence but mechanistically coherent.

Dose used in the trial: 2 g/day. Sarcosine is generally well tolerated.

Selenium

Lower selenium levels have been found in OCD patients compared to controls in multiple studies. A 2017 double-blind RCT found 200 mcg/day selenium supplementation for 8 weeks reduced Y-BOCS scores significantly more than placebo in OCD patients. The mechanism may relate to selenium's role in glutathione peroxidase activity and oxidative stress reduction in the brain.

This is relatively small-scale evidence but selenium is safe at 200 mcg/day (well below the 400 mcg upper limit) and inexpensive.

Omega-3

Omega-3 EPA has modest OCD data. A 2012 RCT in children with OCD found omega-3 augmentation of SSRIs superior to placebo augmentation. Adult data is limited but mechanistically coherent via anti-inflammatory and neuroplasticity effects.

The Right Framework

These supplements are adjuncts to proven OCD treatment—not alternatives. CBT with ERP remains the most evidence-based treatment available. SSRIs are first-line pharmacotherapy. If standard treatment is yielding only partial response, discussing adjunctive supplements with your psychiatrist is a reasonable conversation.

The relative priorities: start with CBT and SSRI optimization, consider NAC as first adjunctive supplement given its evidence quality, then inositol or sarcosine if needed.

FAQ

Q: Are there any risks in taking these supplements with SSRIs for OCD?

NAC and selenium have minimal interaction concerns with SSRIs. Inositol has theoretical overlap with serotonin pathways but no documented harmful interactions. Disclose all supplements to your prescribing psychiatrist regardless.

Q: How long do these supplements take to show effects for OCD?

NAC trials showed benefit at 12 weeks. Inositol effects appeared within 4-6 weeks in trials. OCD treatment timelines are longer than depression—give any adjunct at least 12 weeks.

Q: Can these supplements help with OCD even without SSRI treatment?

Inositol has standalone evidence. NAC's most robust data is as augmentation. For SSRI-naive patients, inositol is the better standalone option.

Q: Is there evidence for any supplements for the intrusive thoughts of OCD specifically?

No supplement has been shown to specifically reduce intrusive thoughts in isolation. ERP therapy remains the most effective intervention for obsessions specifically. Supplements appear to reduce overall OCD severity, including compulsions and distress.

Track your supplements in Optimize.

Supplements for OCD: Adjunctive Options with Evidence